Objective-Serum uric acid (UA) has been associated with increased risk of cardiovascular and metabolic diseases.
U ric acid (UA), the final product of purine degradation, has been associated with obesity, metabolic syndrome, dysglycemic conditions, diabetes mellitus, hypertension, endothelial dysfunction, cardiovascular disease, and chronic kidney disease, most likely as a consequence of westernized lifestyle and environment. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, the causal mechanisms linking elevated UA levels to cardio-metabolic and vascular disease are still unsettled. UA is a powerful scavenger of free radicals accounting for approximately half of the antioxidant capacity of human plasma.
14 It has been suggested that the increase in UA serum levels represents an adaptive response developed by the organism against the detrimental effects of excessive oxidative stress, which characterizes cardio-metabolic and vascular diseases. 15 Conversely, cellular studies have demonstrated that UA may also exert pro-oxidant effects depending on its chemical microenvironment. [16] [17] [18] [19] [20] [21] One potential explanation for how UA might contribute to cardio-metabolic and vascular disease is that it might possess the ability to induce systemic inflammation, aside of its effects at a cellular level. 4 There is evidence that UA can induce inflammatory reactions in human vascular cells, murine kidney tubular cells, and pancreatic β-cells of mice treated for 4 weeks with daily intraperitoneal injections of UA. 16, 22, 23 Thus, it is plausible that an elevation in serum UA as that observed in cardio-metabolic disorders may promote the expression of hepatic acute-phase reactants resulting in higher circulating levels of inflammatory biomarkers. Among markers of inflammation, the most reliable for clinical practice is highsensitivity C-reactive protein (CRP), but other markers such as erythrocyte sedimentation rate, ferritin, complement C3, and fibrinogen have been associated with cardio-metabolic disease. [24] [25] [26] In addition, there is evidence that complement C3
and fibrinogen interact with each other producing clots more resistant to lysis, 27 thus providing a link between inflammation and prothrombotic state.
In an attempt to clarify the relationship of UA with the systemic inflammatory response, we investigated the relationship between serum UA levels and inflammatory biomarkers in a large cohort of nondiabetic adult individuals. Next, we examined the effect of UA on hepatic expression of inflammatory biomarkers, including CRP, ferritin, complement C3, and fibrinogen, and characterized the signaling pathway by which UA stimulates inflammatory response.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Cross-Sectional Study in a Large Sample of Nondiabetic Individuals
Clinical characteristics and laboratory findings of the study group are shown in Table 1 . Of the 2731 subjects examined, 1729 (63.3%) had normal glucose tolerance, and 1002 (36.7%) had abnormal glucose homeostasis comprising impaired fasting glucose or impaired glucose tolerance, and 1253 (45.9%) subjects were hypertensive treated with antihypertensive medications. Men were older, and exhibited a worse metabolic risk profile including higher values of waist circumference, smoking status, blood pressure, triglycerides, fasting glucose, 2 hours postload glucose, HbA1c (glicated hemoglobin), fasting insulin, homeostasis model assessment index of insulin resistance, and UA. By contrast, inflammatory biomarkers were higher in women with the exception of ferritin levels.
To examine the association between UA levels and inflammatory biomarkers, the study group was stratified according to quartiles of UA. As shown in Table 2 , significant differences between the 4 groups were observed with respect to sex (higher prevalence of men in quartiles 3 and 4), age, and adiposity assessed by body mass index or waist circumference, and, therefore, all analyses were adjusted for age, sex, and body mass index. As shown in Table 2 , subjects in the intermediate and high UA quartiles displayed progressively higher levels of total cholesterol, triglycerides, fasting and 2 hours post-load glucose levels, fasting insulin, and homeostasis model assessment index of insulin resistance, and lower concentrations of high-density lipoprotein cholesterol in comparison to individuals in the lowest quartile of UA after adjusting for age, sex, and body mass index. No differences were observed for smoking status, while subjects in the intermediate and high UA quartiles displayed a graded increase of anti-hypertensive medications and a greater proportion of dysglycemia. The association between UA levels and inflammatory biomarkers in the study group stratified according to quartiles of UA is shown in Table 3 . After adjusting for age, sex, and body mass index, subjects in the intermediate and high UA quartiles displayed progressively higher levels of high-sensitivity CRP, fibrinogen, erythrocyte sedimentation rate, ferritin, and complement C3. The difference remained statistically significant after further adjustment for anti-hypertensive treatments and diuretics use.
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Effects of UA on mRNA Expression of CRP, Fibrinogen, Ferritin, and Complement C3 in Human Hepatoma HepG2 Cells
To gain insight into the possible proinflammatory role of UA in hepatic acute-phase reactants expression, HepG2 cells, a well-differentiated human hepatoma cell line, were incubated with increasing UA concentration (29.7, 59.5, 297.4, and 594.8 µmol/L) for 24 hours, and mRNA expression of fibrinogen, ferritin, CRP, and complement C3 (C3) reactants was measured by quantitative real-time polymerase chain reaction technique.
As shown in Figure 1 , UA treatment significantly increased mRNA expression of fibrinogen, ferritin, C3, and CRP in a dose-dependent manner, with maximal effect occurring at 594.8 µmol/L when compared with control untreated HepG2 cells (up to P<0.01). In humans, the main urate transporter is URAT1. To confirm that URAT1 (SLC22A12) was expressed in HepG2 cells, Western blot analyses were performed on whole HepG2 cell lysates. Human embryonic kidney HEK293 cells were used as positive control. As shown in Figure 2A , URAT1 transporter was detected by immunoblotting in HepG2 cells in an amount comparable to HEK293 cells.
UA Activates the IκB Kinase-NF-κB Pathway
To investigate the signal transduction pathway involved in UA-induced expression of inflammatory biomarkers, we evaluated whether UA acts by stimulating the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway. The classical (canonical) pathway leading to the activation of NF-κB involves an IκB kinase (IKK [NF-kB inhibitor]) complex consisting of catalytic kinase subunits Comparisons between the 4 groups were performed using a general linear model. P values refer to results after analyses with adjustment for age, sex, and BMI. ACE indicates angiotensin-converting enzyme; BMI, body mass index; DBP, diastolic blood pressure; F, female; HDL, high-density lipoprotein; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; HbA1c, glicated hemoglobin; HOMA-IR, homeostasis model assessment index of insulin resistance; M, male; NGT, normal glucose tolerance; and SBP, systolic blood pressure.
*P values refer to results after analyses with adjustment for sex. †P values refer to results after analyses with adjustment for age and sex.
(IKKα and IKKβ) and the regulatory nonenzymatic scaffold protein NEMO. On activation, the IKK complex phosphorylates IκB leading to its degradation. This enables the active NF-κB transcription factor subunits to translocate to the nucleus and induce target gene expression. As shown in Figure  2B and 2C, the treatment of HepG2 cells with UA resulted in a dose-dependent phosphorylation of IKK at Ser-180 site (up to 2.2-fold over basal; P<0.01) and IκBα at Ser-32 site (up to 2.0-fold over basal; P<0.01), respectively. Notably, preincubation with benzbromarone (50 µmol/L), a specific inhibitor of UA transporters, reversed the UA-induced increase in IKK and IκB phosphorylation ( Figure 3 A and 3B) . Accordingly, UA stimulated NF-κB p65 phosphorylation at Ser-536, which leads to enhanced transactivation, and induced the transcriptional activity of NF-κB subunit p65 in a dose-dependent fashion ( Figure  4A and 4B). Both NF-κB phosphorylation and activation were inhibited in the presence of benzbromarone ( Figure 4A and 4B). In addition, preincubation with benzbromarone reversed the UA-induced increase in mRNA expression of fibrinogen, ferritin, CRP, and C3 ( Figure 5A through 5D ). There is evidence that UA stimulates production of reactive oxygen species, which, in turn, have various stimulatory 
Discussion
There is compelling evidence that elevated levels of UA are associated with metabolic and cardiovascular disease. 2, 3, 6, 8, 9, 12 Indeed, increased levels of serum UA have been documented in cross-sectional studies in individuals with obesity, metabolic syndrome, insulin resistance, impaired glucose metabolism, classical and nonclassical cardiovascular risk factors, and endothelial dysfunction. [33] [34] [35] [36] [37] [38] [39] Numerous prospective observational studies have shown that hyperuricemia is an independent predictor for both type 2 diabetes mellitus and A, NF-κB phosphorylation levels at S536 were analyzed through immunoblotting with specific primary antibodies. To normalize the blots for protein levels, the blots were stripped and reprobed with specific total protein antibodies. The bar graphs represent means±SD from 3 independent experiments, representative Western blot images are shown. B, NF-κB activity in nuclear lysates has been evaluated using a specific NF-κB ELISA assay; data are means±SD of 3 independent experiments, run in triplicate, *P<0.01 and **P<0.05 vs control, #P<0.01 and ##P<0.05 vs uric acid (UA) 594.8 mmol/L. cardiovascular disease. [1] [2] [3] [4] [5] 11 However, the underlying mechanisms, by which hyperuricemia is linked to an increased risk of type 2 diabetes mellitus and cardiovascular disease, are still unsettled. In addition, despite a clear association between serum UA levels and metabolic and cardiovascular disease, the pathogenic role of UA in these conditions has been questioned, and UA has been viewed as biologically inert or possibly anti-inflammatory because of its antioxidant function.
Several experimental and prospective studies have reported an association between elevated serum levels of acute-phase reactants, indicating chronic subclinical inflammation, with cardiovascular disease and type 2 diabetes mellitus leading to the hypothesis that atherosclerotic cardiovascular disease and type 2 diabetes mellitus arise from a "common soil," 40 and chronic inflammation may be such a candidate. There is some evidence suggesting that UA may induce the expression of inflammatory molecules in human vascular cells and in kidney tubular cells from mice. 16, 22, 23 However, whether UA stimulates the expression of acute-phase reactants in human hepatocytes, the major source of acute-phase proteins/inflammatory biomarkers, is unclear. These observations, coupled with the accessibility of a large well-characterized cohort of nondiabetic adult individuals, have provided the rationale for examining the existence of a mechanism linking UA to inflammation.
In this study, we report a positive relationship between serum UA and acute-phase reactants, such as high-sensitivity CRP, fibrinogen, ferritin, complement C3, and erythrocyte sedimentation rate. Importantly, the relationship remains significant after adjustment for several confounders potentially affecting either serum UA or inflammatory biomarkers levels, including age, sex, adiposity, anti-hypertensive treatments, or diuretics use. To clarify the relationship of UA with the systemic inflammatory response, we investigated the effect of UA on the expression of inflammatory molecules including high-sensitivity CRP, fibrinogen, ferritin, and complement C3 in cultured human hepatoma cells. We found that UA stimulates the expression of CRP, fibrinogen, ferritin, and complement C3 in a dose-dependent fashion. Notably, we found that the proinflammatory effects were abrogated by benzbromarone, a specific inhibitor of UA transporters, thus indicating that the inflammatory effect of UA is specific, and not because of a toxic effect on cells. Also, we provide evidence that UA induces the proinflammatory effect through the NF-κB signaling pathway. NF-κB is a protein complex that controls the transcription of several cytokines and inflammatory molecules. In unstimulated cells, NF-κB is silenced and its heterodimers are retained in the cytoplasm by a family of inhibitors, named IκBs. Activation of the classical pathway of NF-κB involves the phosphorylation of IκB by the IKK complex, leading to IκB ubiquitination and proteasomal degradation. This allows the release and translocation of NF-κB to the nucleus where it turns on the expression of specific downstream genes. We show that UA induces the phosphorylation of IKK at Ser-180 site and IκBα at Ser-32 followed by subsequent stimulation of NF-κB activity. We have previously shown that UA induces oxidative stress in HepG2 as detected by measuring nitrotyrosine levels of intracellular proteins. 21 Herein, we show that the activation of the NF-κB signaling pathway in response to UA is attenuated by treatment with the antioxidant N-acetylcysteine, suggesting that UA elicits proinflammatory response in hepatocytes by inducing oxidative stress.
Strengths of this study include the large sample size comprising men and women, the demographically homogeneous group of Italians from European ancestry, the exclusion of confounding chronic disorders potentially affecting both UA and inflammatory biomarkers, the clinical and laboratory variables collected by trained professionals in a standardized manner, and maintained in a constantly updated database with a low rate of missing data, the centralization of laboratory analyses, the inclusion of several well-validated inflammatory biomarkers, and the use of OGTT and HbA1c data to carefully diagnose diabetes mellitus. However, the study has some limitations. The first limitation of our study is that each test for diabetes mellitus diagnosis (HbA1c and OGTT) was only performed once. Although such an approach is a common limitation to many large epidemiological studies, the day-to-day variability of glucose parameters cannot be taken into account. The second limitation of this study is the cross-sectional design, making causal interpretations of associations between UA levels and inflammatory biomarkers risk difficult. In addition, the present findings are only based on White Europeans, and should not be simply extrapolated to other ethnic groups. Furthermore, this study is based on outpatients recruited at a referral university hospital, representing subjects carrying at least one cardiometabolic risk factor, and, therefore, the present results may not be extendible to the general population. Moreover, the in vitro data suggest that UA induces inflammatory molecules by activating the NF-κB signaling pathway, but the possibility that UA regulates inflammatory molecules expression by signaling mechanisms other than NF-κB could not be excluded. Altogether, the results of this study demonstrate a strong relationship between UA and inflammatory biomarkers. We provide experimental evidence that UA induces the expression of hepatic inflammatory molecules by activating NF-κB signaling, a principal pathway mediating proinflammatory response to various stimuli. Because inflammation has an important pathogenic role in metabolic and cardiovascular disease, our study shed new light on understanding the mechanism by which hyperuricemia may contribute to organ damage.
